Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6MW3511 in advanced solid tumors
NCT05524194Phase 2Unknown
- Sponsor
- Mabwell
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of 6MW3511 in solid tumor, sponsored by Mabwell. Primary endpoints: Number of participants with a Dose Limiting Toxicity and Number of participants with adverse events. Status: unknown.
02
Drugs
6MW3511
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05524194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524194.